Grifols S.A Cash Flow Conversion Efficiency
Grifols S.A cash flow conversion efficiency. Based on the latest financial reports, Grifols S.A (G0FB) has a cash flow conversion efficiency ratio of 0.057x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€430.86 Million ≈ $503.73 Million USD) by net assets (€7.60 Billion ≈ $8.89 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Grifols S.A (2016–2025)
Cash flow conversion efficiency of Grifols S.A from 2016 to 2025. This chart illustrates how Grifols S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Grifols S.A for real-time trading data and today's change.
Grifols S.A Cash Flow Conversion Ratio Explained
Grifols S.A cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Grifols S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Grifols S.A ranked by their cash flow conversion efficiency. Also see how much is Grifols S.A worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yonyou Network Technology Co Ltd
SHG:600588
|
-0.001x |
|
SICC Co. Ltd.
SHG:688234
|
-0.030x |
|
Softcat plc
F:SF5
|
0.107x |
|
Jiangxi Copper Company Limited
F:JIX
|
0.107x |
|
EPR Properties
NYSE:EPR
|
-0.049x |
|
ENTAIN PLC UNSP.ADR/1
F:6GI0
|
N/A |
|
HYBE Co. Ltd
KO:352820
|
0.000x |
|
Zhejiang Crystal Optech Co Ltd
SHE:002273
|
0.032x |
Annual Cash Flow Conversion Efficiency for Grifols S.A (2016–2025)
The table below shows the annual cash flow conversion efficiency of Grifols S.A from 2016 to 2025. Review G0FB FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €7.60 Billion ≈ $8.89 Billion |
€1.05 Billion ≈ $1.22 Billion |
0.138x | +31.40% |
| 2024-12-31 | €8.61 Billion ≈ $10.06 Billion |
€902.00 Million ≈ $1.05 Billion |
0.105x | +260.06% |
| 2023-12-31 | €7.51 Billion ≈ $8.78 Billion |
€218.69 Million ≈ $255.67 Million |
0.029x | +2365.22% |
| 2022-12-31 | €8.46 Billion ≈ $9.89 Billion |
€-10.87 Million ≈ $-12.70 Million |
-0.001x | -101.75% |
| 2021-12-31 | €8.15 Billion ≈ $9.52 Billion |
€596.98 Million ≈ $697.93 Million |
0.073x | -55.65% |
| 2020-12-31 | €6.72 Billion ≈ $7.86 Billion |
€1.11 Billion ≈ $1.30 Billion |
0.165x | +98.81% |
| 2019-12-31 | €6.85 Billion ≈ $8.00 Billion |
€568.93 Million ≈ $665.14 Million |
0.083x | -47.07% |
| 2018-12-31 | €4.70 Billion ≈ $5.49 Billion |
€737.43 Million ≈ $862.13 Million |
0.157x | -32.21% |
| 2017-12-31 | €3.63 Billion ≈ $4.25 Billion |
€841.75 Million ≈ $984.09 Million |
0.232x | +56.07% |
| 2016-12-31 | €3.73 Billion ≈ $4.36 Billion |
€553.28 Million ≈ $646.84 Million |
0.148x | -- |
About Grifols S.A
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, … Read more